Result: Five SDRMs increased in prevalence among NRTI-experienced persons including K65R, K70E, Y115F, and M184V/I.
Nationwide Study of Drug Resistance Mutations in HIV-1 Infected Individuals under Antiretroviral Therapy in Brazil.
PMID: 34069929
2021
International journal of molecular sciences
Result: The most common SDRM (Figure 1, Supplementary Table S2) were the substitutions in RT amino acids M184V (65.53%, n = 13,265), K103N (40.20%, n = 8738), and M41L (17.21%, n = 3480).
Result: The most common mutation across the years was M184V (Figure 1), notwithstanding a decreasing trend and a significant decrease between 2015 (68.29%, n = 1874) and 2016 (53.21%, n = 2684) (p < 0.001) (Table 2).
Discussion: Along with the most common mutations, M184V rates presented a decrease over the yrs (76.88% in 2008 to 51.48% in 2017).
Discussion: Also in line with previous studies is the finding of M184V (65.53%), K103N (40.20%), and M41L (17.21%) as the most common
Surveillance of Pretreatment Drug Resistance Among HIV-Infected Children in Ibadan, Nigeria.
PMID: 34074135
2021
AIDS research and human retroviruses
Abstract: Three out of the four mutations were identified as non-nucleoside reverse transcriptase inhibitors DRM (K103N), whereas the fourth had nucleoside reverse transcriptase inhibitors DRM (M184V).
Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Abstract: Crystallography of HIV RTY115F/F116Y/Q151M/F160M/M184V, mimicking HBV RT L180M/M204V, showed that the F115 bulge (F88 in HBV RT) caused by the F160M mutation induced deviated binding of dCTP from its normal tight binding position.
High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.
Abstract: The DRMs most frequent were M184I/V (82.9%) for nucleoside reverse transcriptase inhibitors (NRTI), K103N/S (63.4%) for nonnucleoside reverse transcriptase inhibitor (NNRTI), and V82A/L/M (7.3%) for protease inhibitors (PI).
Discussion: An elevated frequency of M184V (75%) was also detected herein, as well as in the study conducted in Belem; this has ranged from 54.4% in Sao Paulo to 81.2% in Bahia.
Discussion: Despite the low impact of the M184V alone to NRTI resistance, when taken together to other
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients During Lamivudine Plus Dolutegravir Maintenance Therapy in Clinical Practice.
PMID: 34327247
2021
Open forum infectious diseases
Abstract: In this dataset from clinical practice investigating the impact of past nucleoside reverse-transcriptase inhibitor resistance on this strategy, the combination of M184V/I plus at least
Discussion: However, previous observational studies suggested an increased risk of VF during 3TC-based DT when M184V/I was present in combination with a shorter time of viral suppression.
Discussion: Indeed, M184V/I and TAMs appear to synergize with each other since TAMs alone were not associated with VF.
Discussion: Our study showed that a shorter duration of virological suppression and the presence of M184V/I were independent predictors of VF; however, M184V/I alone was less accurate in predicting the outcome than its combination with TAMs.
Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.
Abstract: The TDF/FTC DRMs included K65R (8/13), M184I/V (5/13), and Y115F (2/13).
Introduction: The main drug resistance mutations (DRMs) to TDF/FTC include K65R and M184I/V, but the global
Result: K65R is known to confer high-level resistance to TDF and intermediate-level resistance to FTC, while M184I/V confers high-level resistance to FTC and 3TC and low-level resistance to abacavir (ABC).
Result: The mutations included K65R (61.5%, 8/13), M184I/V (38.5%, 5/13), and Y115F (2/13).
Table: M184M/V
Table: M184V
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
Abstract: CONCLUSIONS: In this real-world cohort, the majority of whom had virus with the M184V/I and >= 1 additional NA mutation, switching to DTG functional mono-or dual therapy with a non-cytosine NA resulted in persistent HIV-1 RNA >= 50 copies/mL in 18%.
Abstract: Historical genotypes indicated that all had an M184V/I, and 23 (59%) had an M184V/I and >= 1 additional NA mutation.
Introduction: In both the GEMINI and TANGO studies, patients with baseline nucleoside reverse transcriptase inhibitor (NRTI) resistance include those with M184V/I and integrase strand transfer inhibitor (INSTI) resistance were excluded.
Introduction: Prior reports have demonstrated a h
Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in China, 2000-2016.
Abstract: The most frequent mutation was M46L (58, 0.89%), followed by K103N (36, 0.55%), M46I (36, 0.55%), and M184V (26, 0.40%).
Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy.
PMID: 34189182
2021
Open forum infectious diseases
Abstract: We describe a case of treatment-emergent resistance to bictegravir in a person recently diagnosed with human immunodeficiency virus who developed M184V and R263K mutations while on therapy.
Discussion: Neither the M184V (RT) mutation nor the R263KR (INI) mutation was observed in the 2 pretreatment genotypes, suggesting that these were treatment-emergent mutations and were not transmitted or present at baseline.
Discussion: The M184V (RT) mutation was detected after 17 weeks of therapy, and at week 37 the R263KR (INI) mutation was detected via bulk sequencing (Viracor Lab, Missouri) necessitating a change in ART.
HIV mutation literature information.
PMID: 
2021
Viruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT